CORT · Insider Trading
Corcept Therapeutics Inc.
Every open-market purchase and sale reported by CORT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-16 | James N Wilson | Director | Sell | −10,000 | −$1.15M |
| 2026-10-05 | Justin Frederick Gunn | See Remarks | A | +100,000 deriv. | — |
| 2026-10-05 | Sean Maduck | See Remarks | MIXED | — | −$2.70M |
| 2026-10-05 | Roberto Wandenkolk Vieira | President, Oncology | MIXED | — | −$787.21K |
| 2026-10-05 | Joseph Douglas Lyon | See Remarks | MIXED | — | −$991.88K |
| 2026-09-28 | Gary Charles Robb | Chief Business Officer | G | −7,100 | — |
| 2026-09-18 | Roberto Wandenkolk Vieira | President, Oncology | Sell | −296 | −$29.84K |
| 2026-09-18 | Gary Charles Robb | Chief Business Officer | M | +17,493 | +$144.67K |
| 2026-09-16 | James N Wilson | Director | Sell | −10,000 | −$1.11M |
| 2026-09-16 | Joseph Douglas Lyon | See Remarks | MIXED | — | −$1.01M |
| 2026-09-03 | William Guyer | Chief Development Officer | A | +328 | +$18.59K |
| 2026-09-03 | Gary Charles Robb | Chief Business Officer | MIXED | +237 | +$8.28K |
| 2026-09-03 | Joseph Douglas Lyon | See Remarks | MIXED | +188 | +$6.58K |
| 2026-09-03 | Atabak Mokari | Chief Financial Officer | MIXED | +174 | +$4.08K |
| 2026-09-03 | Roberto Wandenkolk Vieira | President, Oncology | MIXED | +174 | −$5.19M |
| 2026-09-03 | Sean Maduck | See Remarks | MIXED | +183 | −$2.65M |
| 2026-08-28 | Kimberly Park | Director | MIXED | — | −$3.27M |
| 2026-08-27 | Sean Maduck | See Remarks | MIXED | — | −$3.54M |
| 2026-08-20 | David L Mahoney | Director | Sell | −103,606 | −$12.25M |
| 2026-08-18 | Gary Charles Robb | Chief Business Officer | MIXED | −10,125 | −$1.16M |
| 2026-08-18 | James N Wilson | Director | Sell | −10,000 | −$1.11M |
| 2026-08-18 | Sean Maduck | See Remarks | MIXED | — | −$389.19K |
| 2026-08-14 | Gary Charles Robb | Chief Business Officer | G | −5,530 | — |
| 2026-08-12 | William Guyer | Chief Development Officer | MIXED | — | −$1.50M |
| 2026-08-12 | Sean Maduck | See Remarks | MIXED | — | −$109.54K |
| 2026-08-06 | William Guyer | Chief Development Officer | MIXED | — | −$338.46K |
| 2026-08-06 | William Guyer | Chief Development Officer | MIXED | — | −$338.46K |
| 2026-08-05 | Joseph Douglas Lyon | See Remarks | Sell | −1,540 | −$175.81K |
| 2026-08-05 | Sean Maduck | See Remarks | MIXED | — | −$2.16M |
| 2026-08-03 | Atabak Mokari | Chief Financial Officer | MIXED | — | −$7.33M |
| 2026-07-17 | Atabak Mokari | Chief Financial Officer | MIXED | — | −$2.65M |
| 2026-07-17 | James N Wilson | Director | Sell | −10,000 | −$882.99K |
| 2026-07-08 | William Guyer | Chief Development Officer | MIXED | — | −$1.43M |
| 2026-07-08 | Gary Charles Robb | Chief Business Officer | G | −600 | — |
| 2026-07-06 | Sean Maduck | See Remarks | MIXED | — | −$2.00M |
| 2026-06-18 | David L Mahoney | Director | Sell | −20,000 | −$1.69M |
| 2026-06-18 | James N Wilson | Director | Sell | −10,000 | −$832.05K |
| 2026-06-17 | Atabak Mokari | Chief Financial Officer | MIXED | — | −$2.48M |
| 2026-06-04 | William Guyer | Chief Development Officer | MIXED | — | −$979.00K |
| 2026-06-03 | Gary Charles Robb | Chief Business Officer | MIXED | +1,194 | +$29.44K |
| 2026-06-03 | Atabak Mokari | Chief Financial Officer | MIXED | +873 | −$2.01M |
| 2026-06-03 | Sean Maduck | See Remarks | MIXED | +778 | −$1.54M |
| 2026-06-03 | William Guyer | Chief Development Officer | A | +1,754 | +$61.78K |
| 2026-06-03 | Joseph Douglas Lyon | See Remarks | MIXED | +805 | +$18.88K |
| 2026-06-02 | Joseph K Belanoff | Chief Executive Officer | MIXED | −12,837 | −$895.25K |
| 2026-05-29 | James N Wilson | Director | G | −892,056 | — |
| 2026-05-29 | Sean Maduck | See Remarks | MIXED | — | −$4.30M |
| 2026-05-29 | Joseph Douglas Lyon | See Remarks | Sell | −5,000 | −$325.00K |
| 2026-05-26 | Kimberly Park | Director | A | +12,500 deriv. | — |
| 2026-05-26 | David L Mahoney | Director | A | +12,500 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| G Leonard Baker Jr | Director | 4,454,934 | $361.38M |
| David L Mahoney | Director | 1,163,939 | $94.42M |
| James N Wilson | Director | 1,057,889 | $85.82M |
| Joseph K Belanoff | Chief Executive Officer | 393,154 | $31.89M |
| Hazel Hunt | Chief Scientific Officer | 255,437 | $20.72M |
| Sean Maduck | See Remarks | 68,525 | $5.56M |
| Gary Charles Robb | Chief Business Officer | 34,627 | $2.81M |
| Atabak Mokari | Chief Financial Officer | 16,304 | $1.32M |
| Roberto Wandenkolk Vieira | President, Oncology | 11,179 | $906.84K |
| Joseph Douglas Lyon | See Remarks | 6,493 | $526.71K |
| William Guyer | Chief Development Officer | 4,313 | $349.87K |
| Daniel N Swisher JR | Director | 2,200 | $178.46K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CORT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.